ERG rearrangements are found in 40–50% of the prostate carcinomas, ETV1 rearrangements/overexpression in 8–10%, and rearrangements involving ETV4, ETV5, or FLI1 in 2–5% of the cases, being mutually exclusive [4]. Here, ETV1 is linked to prostate carcinoma.